Avoiding Duplicate Simulated-Use Work by Leveraging an Already Marketed Safety Feature

Client profile: International manufacturer preparing a 510(k) for a medical device incorporating a sharps-injury-prevention feature.

The Challenge

The manufacturer assumed a new, standalone usability / simulated-clinical-use program would automatically be required for the safety feature before the 510(k) could be filed. That approach would have added study planning, healthcare-professional recruitment, sample preparation, execution, analysis, and report-writing before submission.

The Route That Could Have Cost More Time or Money

Commissioning a new simulated-use study simply because the new device contained a sharps-safety mechanism, without first checking whether FDA guidance allowed existing legally marketed evidence to be leveraged.

What We Did

• Reviewed the exact safety-feature design, activation method, intended users, use environment, and risk controls against FDA’s device-specific sharps-injury-prevention guidance.
• Identified a legally marketed device in which the same sharps-injury-prevention feature was already used, and assessed whether the feature could be appropriately identified in the 510(k) in lieu of repeating simulated clinical-use testing.
• Built a side-by-side comparison covering intended use, design features, specifications, materials, activation, safety performance, labeling, and relevant differences.
• Confirmed which performance evidence still needed to be generated for the new device itself and separated that from evidence specific to the already marketed sharps-safety feature.
• Prepared the regulatory rationale so that the decision was evidence-based rather than presented as a blanket “usability not required” statement.

What NKB Did Differently

We started with the FDA device-specific guidance and the legally marketed safety feature, not with a default testing checklist. The key question became: “What new evidence is genuinely needed for this device, and what evidence is already established for the same safety feature?”

How It Helped

This prevented the client from automatically commissioning a duplicate simulated-use program before establishing whether FDA’s own guidance supported reliance on the already marketed feature.

Business / Regulatory Impact

A leaner evidence plan, fewer unnecessary pre-submission activities, and a 510(k) strategy focused on the performance questions that actually remained for the new device.

NKB Insight

Good regulatory strategy does not remove testing by assumption. It identifies when FDA already provides a defensible route to avoid repeating evidence that is genuinely transferable.